Arrowhead Pharmaceuticals (ARWR) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ARWR Arrowhead Pharmaceuticals

Watchlist

18.521
-0.189-1.01%

Trading Nov 21 15:27 ET

2.30BMarket Cap-3982P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Shareholders in Arrowhead Pharmaceuticals (NASDAQ:ARWR) Have Lost 75%, as Stock Drops 13% This Past Week
Simply Wall StNov 21 06:11 ET
Earnings Preview: ARWR to Report Financial Results Post-market on November 26
Moomoo NewsNov 20 20:00 ET
Arrowhead Pharmaceuticals Price Target Maintained With a $60.00/Share by HC Wainwright & Co.
Dow JonesNov 20 13:17 ET · Ratings
Arrowhead Pharmaceuticals' Potential Approval of Clozasiran Drives Buy Rating and $60 Price Target
TipRanksNov 20 12:35 ET · Ratings
Piper Sandler Sticks to Its Buy Rating for Arrowhead Pharmaceuticals (ARWR)
TipRanksNov 19 06:47 ET · Ratings
Citi Maintains Arrowhead Pharmaceuticals(ARWR.US) With Hold Rating, Maintains Target Price $27
Moomoo NewsNov 19 03:36 ET · Ratings

Comments

stockhub

Apr 7 11:23

Hope price action is consistent with result

Plozasiran reduced triglycerides and APOC3 up to a mean maximum of 86% and 90% respectively in patients with severe hypertriglyceridemia
$Arrowhead Pharmaceuticals (ARWR.US)$

Mooers' Insights

Tonyco

Apr 6 22:01

$Arrowhead Pharmaceuticals (ARWR.US)$
Insiderd selling shares and financials dont look good. Im guessing they dont have anything in the pipeline?

Moomoo AI

Mar 8 05:54

The company's poor performance and the CEO's high pay, despite falling earnings and shareholder value, may upset shareholders. The upcoming AGM on March 14th is a chance for shareholders to hold the board and management accountable.